Bristol-Myers will pay Facet $15M milestone fee for cancer drug

01/11/2010 | Boston Globe (tiered subscription model), The

Facet Biotech will get a milestone payment of $15 million from Bristol-Myers Squibb after it started enrolling patients into a Phase II trial of elotuzumab, a multiple myeloma drug. Meanwhile, Bristol-Myers decided not to expand its development deal with Facet for PDL241, an experimental treatment for immune system disorders.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX